🇺🇸 FDA
Patent

US 12338439

Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof

granted A61KA61K31/713A61K45/06

Quick answer

US patent 12338439 (Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/713, A61K45/06, A61K47/549, A61P